In light of role of BET and HDAC proteins as central regulators of chromatin structure and transcription coupled with the evidenced efficacy attained with the combined BET and HDAC inhibition in pancreatic ductal adenocarcinoma at the preclinical level [341], a hybrid scaffold composed of the structural features of a BET inhibitor ( +)-JQ1 and class I HDAC inhibitor CI994 was generated (Fig. 14). The gene discussed is HDAC9; the disease is pancreatic ductal adenocarcinoma.